/CURX

CURX Stock - Curanex Pharmaceuticals Inc Common Stock

Q: What is the analyst price target for CURX?

Analyst price target information is not currently available for CURX.

Q: What is CURX's market cap?

Market capitalization information is not currently available for CURX.

Healthcare|Biotechnology|NASDAQ

$0.37-3.90%

$0.02 (-3.90%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.41

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CURX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.00

52W High$9.18

52W Low$0.37

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022
Revenue	N/A	N/A	$26,000
Gross Profit	N/A	N/A	$4,429
Gross Margin	N/A	N/A	17.0%
Operating Income	$-365,062	$-19,298	$-20,233
Net Income	$-361,506	$-19,198	$-20,233
Net Margin	N/A	N/A	-77.8%
EPS	$-0.01	$-0.00	$-0.02

Company Overview

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. The company was founded in 1996 and is headquartered in Jericho, New York.

Visit Website

Frequently Asked Questions about CURX

What is CURX's current stock price?

Curanex Pharmaceuticals Inc Common Stock (CURX) is currently trading at $0.37 per share. The stock has moved -3.90% today.

What is the analyst price target for CURX?

No analyst price targets are currently available for this stock.

What sector is Curanex Pharmaceuticals Inc Common Stock in?

Curanex Pharmaceuticals Inc Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CURX's market cap?

Curanex Pharmaceuticals Inc Common Stock has a market capitalization of $0.01 billion, making it a small-cap company.

Does CURX pay dividends?

No, Curanex Pharmaceuticals Inc Common Stock does not currently pay a dividend to shareholders.